RU2017119465A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017119465A3 RU2017119465A3 RU2017119465A RU2017119465A RU2017119465A3 RU 2017119465 A3 RU2017119465 A3 RU 2017119465A3 RU 2017119465 A RU2017119465 A RU 2017119465A RU 2017119465 A RU2017119465 A RU 2017119465A RU 2017119465 A3 RU2017119465 A3 RU 2017119465A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140153759A KR101721831B1 (ko) | 2014-11-06 | 2014-11-06 | 로베글리타존을 함유하는 경구 투여용 약제학적 조성물 |
| KR10-2014-0153759 | 2014-11-06 | ||
| PCT/KR2015/011801 WO2016072748A1 (en) | 2014-11-06 | 2015-11-04 | Pharmaceutical compositions comprising lobeglitazone for oral administration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017119465A RU2017119465A (ru) | 2018-12-06 |
| RU2017119465A3 true RU2017119465A3 (ru) | 2019-05-28 |
| RU2709526C2 RU2709526C2 (ru) | 2019-12-18 |
Family
ID=55909398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017119465A RU2709526C2 (ru) | 2014-11-06 | 2015-11-04 | Фармацевтические композиции, которые содержат лобеглитазон, для перорального введения |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR101721831B1 (ru) |
| CN (1) | CN107072954B (ru) |
| CL (1) | CL2017001077A1 (ru) |
| CO (1) | CO2017004382A2 (ru) |
| PE (1) | PE20170909A1 (ru) |
| RU (1) | RU2709526C2 (ru) |
| WO (1) | WO2016072748A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230165301A (ko) * | 2021-04-01 | 2023-12-05 | 아클립스 투 인크. | 신장 질환의 치료 |
| WO2023205683A2 (en) * | 2022-04-20 | 2023-10-26 | Aclipse Two Inc. | Treatment of gastrointestinal diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977158A (en) * | 1996-11-28 | 1999-11-02 | Novo Nordisk A/S | Pharmaceutical formulations comprising levormeloxifene compounds |
| IL163642A0 (en) * | 2002-02-26 | 2005-12-18 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| KR100450700B1 (ko) | 2002-03-22 | 2004-10-01 | 주식회사종근당 | 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물 |
| RU2442585C2 (ru) * | 2007-05-31 | 2012-02-20 | Си Ви Терапьютикс, Инк. | Способ лечения диабета |
| EP2470552B1 (en) * | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US20130171254A1 (en) * | 2009-12-24 | 2013-07-04 | Abbott Healthcare Private Limited | Fast dissolving pharmaceutical composition comprising lornoxicam |
| CN102274162A (zh) * | 2011-08-02 | 2011-12-14 | 无锡万全医药技术有限公司 | 一种含有难溶性药物和亲水凝胶材料的固体组合物及其制备方法 |
| US20150018360A1 (en) * | 2011-09-13 | 2015-01-15 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
-
2014
- 2014-11-06 KR KR1020140153759A patent/KR101721831B1/ko active IP Right Grant
-
2015
- 2015-11-04 PE PE2017000792A patent/PE20170909A1/es unknown
- 2015-11-04 CN CN201580060063.9A patent/CN107072954B/zh active Active
- 2015-11-04 WO PCT/KR2015/011801 patent/WO2016072748A1/en active Application Filing
- 2015-11-04 RU RU2017119465A patent/RU2709526C2/ru active
-
2017
- 2017-05-01 CL CL2017001077A patent/CL2017001077A1/es unknown
- 2017-05-02 CO CONC2017/0004382A patent/CO2017004382A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101721831B1 (ko) | 2017-03-31 |
| CL2017001077A1 (es) | 2018-03-16 |
| CO2017004382A2 (es) | 2017-07-19 |
| CN107072954B (zh) | 2023-05-26 |
| RU2017119465A (ru) | 2018-12-06 |
| KR20160054317A (ko) | 2016-05-16 |
| RU2709526C2 (ru) | 2019-12-18 |
| PE20170909A1 (es) | 2017-07-12 |
| CN107072954A (zh) | 2017-08-18 |
| WO2016072748A1 (en) | 2016-05-12 |